Inhalation CDMO Market Report 2024: Strategies And Recent Developments | Pfizer Inc., Merck KGaA, Baxter's BioPharma Solutions, Lonza Group AG, Catalent Inc., AptarGroup Inc., Samsung Biologics Co. Ltd., Siegfried Holding AG, Recipharm AB

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2132

The Business Research Company offers in-depth market insights through Inhalation CDMO Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The inhalation CDMO market size has grown strongly in recent years. It will grow from $1.94 billion in 2023 to $2.08 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to rising prevalence of respiratory disorders, growing demand for personalized medicine, increasing outsourcing by pharmaceutical companies, growth of the biopharmaceutical industry.The inhalation CDMO market size is expected to see strong growth in the next few years. It will grow to $2.7 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to focus on precision medicine and targeted therapies, rapid expansion of biopharmaceutical inhalation therapies,focus on patient-centric solutions, global market expansion and emerging market opportunities, regulatory support for inhalation drug development. Major trends in the forecast period include increasing demand for digital health solutions, biologic inhalation therapies, focus on sustainable inhaler technologies, integration of artificial intelligence (AI) and machine learning, collaborations and partnerships.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp

Market Segmentation:
The inhalation cdmo market covered in this report is segmented -

1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler
2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
3) By Technology: Manual Inhalers (SMI), Digital Inhalers
4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users

Major Driver - Rising Respiratory Disorders Fueling Growth In Inhalation CDMO Market
The increasing prevalence of respiratory disorders is expected to propel the growth of the inhalation CDMO market going forward. Respiratory disorders are a group of medical conditions that affect the respiratory system, which includes the organs and structures involved in breathing. Inhalation CDMOs are used in the development and manufacturing of products for respiratory disorders due to their expertise in formulating and delivering drugs to the lungs, offering specialized expertise, infrastructure, and resources to pharmaceutical companies seeking to bring innovative inhalation therapies. For instance, in June 2023, according to reports shared by the Australian Institute of Health and Welfare, an Australia-based national agency, there was a rise in respiratory disease-related deaths from 43,031 in 2020 to 46,551 in 2021in Australia. Furthermore, in September 2022, according to the data published by The Lancet, a UK-based book and periodic data publishing organization, 11,255 new cases of RSV were recorded in 2021, which is 11.4% more compared to 9,972 cases in 2020. Therefore, the increasing prevalence of respiratory disorders is driving the growth of the inhalation CDMO market.

Competitive Landscape:
Major companies operating in the inhalation cdmo market report are Pfizer Inc., Merck KGaA, Baxter's BioPharma Solutions, Lonza Group AG, Catalent Inc., AptarGroup Inc., Samsung Biologics Co. Ltd., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, Cambrex Corporation, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Formosa Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Dipharma Francis Srl, Copley Scientific

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Top Trend - Strategic Collaborations Transforming Inhalation CDMO Landscape
Major companies operating in the inhalation CDMO industry are adopting a strategic partnership approach to provide specialized drug development and delivery. A strategic partnership is a long-term, mutually beneficial arrangement between two or more companies that work together to achieve shared goals. For instance, in May 2023, Hovione, a Portugal-based Contract Development and Manufacturing Organization, partnered with H&T Presspart, a UK-based manufacturer of high-precision metal and plastic components for the pharmaceutical industry, to develop Presspart's Sunrise Capsule-based Dry Powder Inhaler platform. This partnership focuses on developing new technologies that can deliver higher doses of drugs and improve the efficiency of drug delivery to the lungs.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Inhalation CDMO Market Characteristics
3. Inhalation CDMO Market Trends And Strategies
4. Inhalation CDMO Market - Macro Economic Scenario
5. Inhalation CDMO Market Size And Growth
…..
27. Inhalation CDMO Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.